HONG KONG, 18 June 2026 — ARC Group today announced that it has committed to invest in Cloudbreak Pharma Inc. (HKEX: 2592), a clinical-stage ophthalmology biotechnology company with operations across the United States and China, following the signing of a share subscription agreement through its wholly owned subsidiary ARC Group International Limited.
The transaction marks a further step in ARC Group’s deployment of capital into cross-border healthcare and life sciences, a priority sector for the firm across both Asian and Western markets.
ARC Group has committed to invest up to US$15.00 million (approximately HK$117.34 million) in Cloudbreak through an equity subscription facility. Cloudbreak intends to use the proceeds to advance its CBT-004 and CBT-199 programmes and wider drug discovery, repay bank borrowings in the People’s Republic of China, and fund working capital and general corporate purposes.
This investment reflects ARC Group’s disciplined approach to deploying capital across Asia through its Asset Management division, identifying high-growth, value-generating businesses that underpin the real economy and are positioned to outperform in an increasingly complex global environment.
Nigel Wong, Head of Asset & Wealth Management commented:
“As healthcare becomes one of the most resilient sources of long-term value in Asia, cross-border life sciences sit at the centre of that shift. ARC Group’s Asset Management division is focused on businesses at the intersection of scientific depth and real commercial discipline, and Cloudbreak is a compelling example. With a strong clinical pipeline, a Hong Kong listing that gives investors real visibility, and operations across two of the world’s most important healthcare markets, it is exactly the kind of business we look to back, and we are excited to support its next phase of growth.”
ARC Group continues to evaluate investment opportunities across Asia with a focus on scalable platforms in healthcare, life sciences, and capital-efficient growth sectors.
About ARC Group
ARC Group is a diversified financial services and asset management platform focused on cross-border investment, capital markets, and strategic advisory across Asia.
Completion of the subscription is subject to the conditions set out in the share subscription agreement and may or may not proceed. Full terms are set out in Cloudbreak Pharma Inc.’s announcement published on the website of The Stock Exchange of Hong Kong Limited on 18 June 2026.
For more information or any questions, please contact:
Nigel Wong
Head of Asset & Wealth Management
[email protected]
For media inquiries, please contact:
Julia Zhang
Marketing Manager
julia.zhang@arc-group.com
